As claimed, referring to the results of clinical trials, the drug's creators LMTX, it can slow down the progression of the disease by 80%, and is the most effective of all existing drugs used in Alzheimer's disease.
"The results we got are unprecedented," said inter alia, Claude Uilčik (Claude Wischik) from Aberdeen University (United Kingdom), one of the founders of the company TauRx Pharmaceuticals, developed the drug LMTX.
NewScientist magazine writes, in clinical trials the drug took part 891 patient with medium or moderately expressed symptoms of Alzheimer's disease. Some of them received LMTX, part took the drug in combination with other drugs, and the rest received a placebo. After 15 months of testing mental ability test participants showed those who took LMTX, they declined significantly less than those who received a placebo.
Patients from the Group of "other better LMTX retained the intellect and ability to cope with such daily tasks as independent dressing or eating. They increasingly have remained emotionally connected with their family members, and one pair, according to Uilčika, even said that the drug allowed them to start a new life. "The wife of one of the patients told me that the husband suddenly got up and fixed a fence in the garden, making what he couldn't do for years," said the scientist.
In General, according to Uilčika, the drug slowed the disease progression by about 80%. Brain scans of patients showed that the process stalled LMTX death of nerve cells on 33-38% compared with placebo.
LMTX-first successful past such large-scale clinical trials of the drug, "running" against the tangles of abnormal Tau protein formed in the neurons of patients with Alzheimer's disease.
It is believed that the accumulation of Tau protein lead to the death of nerve cells, disrupting the normal functioning of the brain. Meanwhile, the goal of all existing drugs for Alzheimer's disease is another cause of abnormal protein, beta-amyloid, which also accumulates in the tissues of the brain of patients forming amyloid plaques and нейродегенеративным changes.
The so-called "amiloidnaâ" hypothesis of developing Alzheimer's disease is now considered mainstream. However, the "antiamiloidnyh" of drugs is very low. The success of clinical trials LMTX speaks in favor of what tangles of Tau protein and not amyloid plaques are the main cause of the onset of symptoms of Alzheimer's disease, indicated in article NewScientist.
Earlier, Australian scientists reported on the creation of a vaccine against Alzheimer's disease. While it tested only on mice, tests on humans will begin in the next 2-3 years.